A novel approach for enhancing the efficacy of PD-L1 targeting antibodies by harnessing beneficial FcγR signaling pathways. Strategy involves either (1) Co-administration of PD-L1 targeting antibodies with an FcγRIIB-blocking antibody or ... Read more

Alzheimer's Disease (AD) is an age-associated neurodegenerative disorder characterized clinically by a decline in cognitive function. It is the most common type of dementia, with 5.8 million Americans living with AS in 2020. ... Read more

Chimeric Antigen Receptor (CAR)-T Cell Therapy is a personalized treatment for cancer in which the patient's T cells are genetically engineered to express a synthetic receptor that binds a tumor antigen. ... Read more

A new class of small molecules offers a targeted strategy for treating Huntington’s disease (HD) and related trinucleotide repeat expansion disorders (TREDs). ... Read more

Non-Small Cell Lung Cancer (NSCLC) is a very common type of cancer, and despite currently available therapies, is one of the deadliest due to the emergence of drug resistance, which results in tumor recurrence. ... Read more

There is a growing need for effective antiviral therapies, particularly for viruses that currently lack approved treatments. ... Read more

LOX is a key driver of fibrosis and tumor progression through its role in extracellular matrix remodeling. We developed a set of LOX inhibitors based on LOX’s natural prodomain (LPD) to treat fibrosis, Duchenne Muscular Dystrophy (DMD), and cancer. ... Read more

Chimeric Antigen Receptor T-Cells (CAR-Ts) are one of the revolutionary technologies of the twenty-first century, invented by Prof. Zelig Eshhar at the Weizmann Institute of Science. ... Read more

A novel gut microbiome-based method has been developed to predict and prevent weight regain after weight loss. ... Read more

A novel method to treat tyrosine kinase inhibitor (TKI) resistant cancer by using a combination of three antibodies that target EGFR (ERBB1), HER2 (ERBB2), and HER3 (ERBB3) receptors. ... Read more